Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
PACB - Pacific Biosciences of California Inc
$36.92
0.00(0.00%)5:00:00 AM 1/15/2021
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. Its single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. The company also provides consumable products, including SMRT cells, as well as various reagent kits designed for specific workflow such as template preparation to convert DNA into SMRTbell double-stranded DNA library formats including molecular biology reagents, such as ligase, buffers and exonucleases. In addition, it provides binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprises reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences has collaboration with Asuragen to develop assays for carrier screening and other applications based on SMRT sequencing technology and AmplideX PCR chemistry; Invitae Corporation focuses on the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.
Stock Chart

Summary:

  • A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.
  • RSI is at a high level of 73. A high level of RSI indicates the stock is overbought.
  • MACD is crossing MACD signal line at 0.6. MACD crossing signal line is bullish signal.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics

Peers

Stock news

    01/13/2021PACB
    Pacific Biosciences Reaches Our Price Target: Now What?

    "This is another great stock," Jim Cramer told viewers of the Lightning Round segment of Mad Money Tuesday evening when asked about Pacific Biosciences of California Inc. . In the daily Japanese candlestick chart of PACB, below, we can see that the shares corrected modestly after our Dec. 9 review and subsequently rallied to the $39 price target. This chart shows that prices are above the rising 50-day moving average line and trade at more than three times the level of the rising 200-day movi...

    01/13/2021PACB
    Pacific Biosciences (PACB) Releases Preliminary Q4 Revenues

    Pacific Biosciences' (PACB) preliminary Q420 revenues are expected to improve from Q320.

    01/13/2021PACB
    Pacific Biosciences and Invitae to Develop Ultra-High-Throughput Clinical Whole Genome Sequencing Platform

    New platform expected to make whole genome sequencing significantly more affordable and accessible for use in mainstream medical careMENLO PARK, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced a multi-year collaboration with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to begin development of a production-scale high-throughput sequencing p...

    01/12/2021PACB
    Pacific Biosciences Grants Equity Incentive Awards to New Employees

    MENLO PARK, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality, long read sequencing platforms, today announced that the Board of Directors granted non-qualified stock options covering an aggregate of 750,000 shares of Pacific Biosciences common stock and restricted stock units (“RSUs”) covering 335,000 shares of Pacific Biosciences common stock to the Company’s recently hir...

    01/11/2021PACB
    Pacific Biosciences of California, Inc. Announces Preliminary Fourth Quarter 2020 Revenue

    MENLO PARK, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (the “Company”) (NASDAQ: PACB), a leading provider of high-quality sequencing platforms, today announced unaudited preliminary revenue of approximately $27 million for its fourth quarter ended December 31, 2020. The Company’s full financial results for the fourth quarter and the fiscal year ended December 31, 2020 are not yet available. Financial and Operational Highlights * Preliminary fourth quarter...

    01/8/2021PACB
    SoftBank Takes Stake in DNA Firm Pacific Biosciences

    (Bloomberg) -- SoftBank Group Corp. has taken a stake of about 6% in Pacific Biosciences of California Inc., a U.S. DNA-sequencing company whose stock has risen sevenfold in the last year, according to a person with knowledge of the investment.The stake, currently worth more than $350 million, highlights the fast-expanding portfolio of public equity investments by SoftBank’s asset management unit SB Northstar, said the person, who asked not to be named as its investment decisions are private. So...

    01/8/2021PACB
    Pacific Biosciences Announces Appointments of Mark Van Oene as Chief Operating Officer and Peter Fromen as Chief Commercial Officer

    MENLO PARK, Calif., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing solutions, today announced the appointments of Mark Van Oene as Chief Operating Officer and Peter Fromen as Chief Commercial Officer, both effective as of January 8, 2021. “I am delighted to have Mark Van Oene and Peter Fromen join the company,” said Christian Henry, President and Chief Executive Officer of Pacific Biosciences. “Mark and Pet...

    01/8/2021PACB
    Wellcome Sanger Institute Increases Investment in PacBio Long-Read Sequencing to Support Darwin Tree of Life Research Initiative

    Seven new Sequel IIe Systems will support expanded generation of high-quality genomes for improving fundamental understanding of biology and aiding biodiversity conservationMENLO PARK, Calif ., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality, long-read sequencing platforms, today announced that the Wellcome Sanger Institute has committed to purchase seven new Sequel IIe Systems and upgrade its five existing Sequel II Sys...